Athenex Inc (ATNX) Given Average Rating of “Hold” by Analysts

Shares of Athenex Inc (NASDAQ:ATNX) have received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $25.00.

A number of equities research analysts recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Athenex in a report on Thursday, October 25th. They issued a “buy” rating and a $27.00 price objective for the company. Zacks Investment Research upgraded shares of Athenex from a “sell” rating to a “hold” rating in a report on Tuesday, October 16th. BidaskClub cut shares of Athenex from a “sell” rating to a “strong sell” rating in a report on Saturday, October 6th. Finally, ValuEngine cut shares of Athenex from a “buy” rating to a “hold” rating in a report on Tuesday, August 14th.

In other Athenex news, CEO Johnson Yiu Nam Lau acquired 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 27th. The stock was purchased at an average cost of $15.66 per share, for a total transaction of $31,320.00. Following the completion of the acquisition, the chief executive officer now owns 2,847,422 shares of the company’s stock, valued at approximately $44,590,628.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jinn Wu acquired 12,500 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was acquired at an average price of $13.47 per share, with a total value of $168,375.00. Following the completion of the acquisition, the director now directly owns 311,208 shares of the company’s stock, valued at approximately $4,191,971.76. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 27,000 shares of company stock valued at $405,120 and sold 344,317 shares valued at $5,859,972. Corporate insiders own 29.50% of the company’s stock.



A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Athenex by 106.3% during the second quarter. BlackRock Inc. now owns 3,472,246 shares of the company’s stock valued at $64,793,000 after acquiring an additional 1,789,061 shares during the period. Northern Trust Corp boosted its holdings in Athenex by 249.8% during the second quarter. Northern Trust Corp now owns 511,476 shares of the company’s stock valued at $9,545,000 after acquiring an additional 365,240 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its holdings in Athenex by 85.5% during the third quarter. Gilder Gagnon Howe & Co. LLC now owns 222,378 shares of the company’s stock valued at $3,456,000 after acquiring an additional 102,524 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Athenex by 66.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 210,889 shares of the company’s stock valued at $3,936,000 after acquiring an additional 84,566 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Athenex by 177.9% during the second quarter. Bank of New York Mellon Corp now owns 163,893 shares of the company’s stock valued at $3,058,000 after acquiring an additional 104,918 shares during the period. Institutional investors own 19.87% of the company’s stock.

NASDAQ ATNX opened at $11.54 on Wednesday. Athenex has a 1-year low of $11.49 and a 1-year high of $20.90. The firm has a market capitalization of $821.03 million, a PE ratio of -4.97 and a beta of -1.66.

Athenex (NASDAQ:ATNX) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.10). The company had revenue of $11.57 million during the quarter. Athenex had a negative return on equity of 73.37% and a negative net margin of 122.29%. Research analysts predict that Athenex will post -1.77 EPS for the current fiscal year.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Read More: Trading Strategy Methods and Types

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply